Considerable light has been thrown on the mechanisms of oral tolerance (or,
more correctly, orally-induced systemic tolerance) in the past 12-18 month
s. While it is very clear that T cell anergy and apoptosis can occur after
being fed antigen, a major pathway that has been described in different mod
els is the induction of regulatory T cells which secrete transforming growt
h factor beta. These cells have been designated Th3 cells but their relatio
n to the in-vitro-generated Tr cells, which inhibit tissue-damaging T cell
responses in the gut mucosa, is not known. An important discovery is that f
ood antigens have major systemic effects on T cells, similar in many ways t
o those seen following intravenous injection of soluble antigens. This conc
eptually moves us away from the notion that there is something special abou
t mucosal (compared to systemic) lymphoid tissue to the notion that ii is t
he type of antigens seen in the gut (i.e, digested, soluble polypeptides) w
hich dictates the types of response seen there. After initial excitement, c
linical trials using oral tolerance to treat autoimmune disease have been s
omewhat disappointing.